Harvest Management LLC Takes $207,000 Position in GW Pharmaceuticals PLC- (GWPH)

Harvest Management LLC acquired a new position in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,200 shares of the biopharmaceutical company’s stock, valued at approximately $207,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. First Republic Investment Management Inc. lifted its stake in shares of GW Pharmaceuticals PLC- by 7.4% during the second quarter. First Republic Investment Management Inc. now owns 10,031 shares of the biopharmaceutical company’s stock worth $1,400,000 after purchasing an additional 688 shares in the last quarter. Van Hulzen Asset Management LLC lifted its stake in shares of GW Pharmaceuticals PLC- by 29.3% during the second quarter. Van Hulzen Asset Management LLC now owns 3,245 shares of the biopharmaceutical company’s stock worth $453,000 after purchasing an additional 735 shares in the last quarter. IFP Advisors Inc lifted its stake in shares of GW Pharmaceuticals PLC- by 103.4% during the third quarter. IFP Advisors Inc now owns 1,448 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 736 shares in the last quarter. Eqis Capital Management Inc. lifted its stake in shares of GW Pharmaceuticals PLC- by 18.3% during the second quarter. Eqis Capital Management Inc. now owns 4,859 shares of the biopharmaceutical company’s stock worth $678,000 after purchasing an additional 750 shares in the last quarter. Finally, Flagship Harbor Advisors LLC acquired a new position in shares of GW Pharmaceuticals PLC- during the second quarter worth about $109,000. Institutional investors own 70.02% of the company’s stock.

GWPH has been the topic of a number of recent research reports. Bank of America restated a “buy” rating and set a $197.00 price objective (up previously from $181.00) on shares of GW Pharmaceuticals PLC- in a research note on Friday, September 28th. Cantor Fitzgerald set a $211.00 target price on GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research report on Thursday, September 27th. BidaskClub raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research report on Saturday, September 22nd. Stifel Nicolaus started coverage on GW Pharmaceuticals PLC- in a research report on Tuesday, August 14th. They set a “buy” rating and a $181.00 target price on the stock. Finally, Morgan Stanley set a $227.00 target price on GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research report on Thursday, October 11th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. GW Pharmaceuticals PLC- currently has an average rating of “Buy” and a consensus price target of $184.13.

Shares of NASDAQ GWPH opened at $137.87 on Friday. GW Pharmaceuticals PLC- has a 1 year low of $105.12 and a 1 year high of $179.65. The company has a quick ratio of 8.21, a current ratio of 8.67 and a debt-to-equity ratio of 0.01.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/11/11/harvest-management-llc-takes-207000-position-in-gw-pharmaceuticals-plc-gwph.html.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Further Reading: What is a Call Option?

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply